Cargando…

Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases

PURPOSE OF REVIEW: Biologics and small molecule inhibitors (SMIs) are a rapidly growing class of highly efficacious therapies in the treatment of chronic immunologic and allergic conditions. With precision targeting of inflammatory signaling molecules, these new agents selectively modulate the immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodson, Joseph, Lio, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643971/
https://www.ncbi.nlm.nih.gov/pubmed/36348149
http://dx.doi.org/10.1007/s11882-022-01047-w
_version_ 1784826642246402048
author Dodson, Joseph
Lio, Peter A.
author_facet Dodson, Joseph
Lio, Peter A.
author_sort Dodson, Joseph
collection PubMed
description PURPOSE OF REVIEW: Biologics and small molecule inhibitors (SMIs) are a rapidly growing class of highly efficacious therapies in the treatment of chronic immunologic and allergic conditions. With precision targeting of inflammatory signaling molecules, these new agents selectively modulate the immune system to treat a variety of conditions. Dermatologic diseases, including atopic dermatitis and psoriasis, are of particular interest due to the growing number of new biologics and SMIs in recent years. This review serves to summarize and evaluate the recent literature regarding biologics and SMIs. RECENT FINDINGS: Currently approved biologics for AD achieve clear or almost clear skin in less than 40% of patients treated. Several biologics that are still under investigation for AD have shown better efficacy in phase III trials with similar safety profiles. Recently approved SMIs for AD also demonstrate a high degree of efficacy, but safety profiles may limit their use. Psoriasis has several highly efficacious biologics on the market; however, only one SMI is currently available. Additional SMIs for psoriasis have completed phase III trials and demonstrated high efficacy. SUMMARY: This article evaluates recent literature on biologics and small molecule inhibitors for AD and psoriasis.
format Online
Article
Text
id pubmed-9643971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96439712022-11-14 Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases Dodson, Joseph Lio, Peter A. Curr Allergy Asthma Rep Allergic Skin Diseases (L Fonacier, Section Editor) PURPOSE OF REVIEW: Biologics and small molecule inhibitors (SMIs) are a rapidly growing class of highly efficacious therapies in the treatment of chronic immunologic and allergic conditions. With precision targeting of inflammatory signaling molecules, these new agents selectively modulate the immune system to treat a variety of conditions. Dermatologic diseases, including atopic dermatitis and psoriasis, are of particular interest due to the growing number of new biologics and SMIs in recent years. This review serves to summarize and evaluate the recent literature regarding biologics and SMIs. RECENT FINDINGS: Currently approved biologics for AD achieve clear or almost clear skin in less than 40% of patients treated. Several biologics that are still under investigation for AD have shown better efficacy in phase III trials with similar safety profiles. Recently approved SMIs for AD also demonstrate a high degree of efficacy, but safety profiles may limit their use. Psoriasis has several highly efficacious biologics on the market; however, only one SMI is currently available. Additional SMIs for psoriasis have completed phase III trials and demonstrated high efficacy. SUMMARY: This article evaluates recent literature on biologics and small molecule inhibitors for AD and psoriasis. Springer US 2022-11-08 2022 /pmc/articles/PMC9643971/ /pubmed/36348149 http://dx.doi.org/10.1007/s11882-022-01047-w Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Allergic Skin Diseases (L Fonacier, Section Editor)
Dodson, Joseph
Lio, Peter A.
Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title_full Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title_fullStr Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title_full_unstemmed Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title_short Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
title_sort biologics and small molecule inhibitors: an update in therapies for allergic and immunologic skin diseases
topic Allergic Skin Diseases (L Fonacier, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643971/
https://www.ncbi.nlm.nih.gov/pubmed/36348149
http://dx.doi.org/10.1007/s11882-022-01047-w
work_keys_str_mv AT dodsonjoseph biologicsandsmallmoleculeinhibitorsanupdateintherapiesforallergicandimmunologicskindiseases
AT liopetera biologicsandsmallmoleculeinhibitorsanupdateintherapiesforallergicandimmunologicskindiseases